Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.

Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD

Atherosclerosis25 May 2010Cited by 150 (Europe PMC)

PMID20557887DOI10.1016/j.atherosclerosis.2010.05.028PepBankPUB-20557887

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In people with impaired glucose tolerance or recent type 2 diabetes, exenatide reduced postprandial triglyceride elevation versus placebo.
In plain wordsIn people with impaired glucose tolerance or recent diabetes, exenatide reduced triglyceride rises after meals versus placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePostprandial triglyceride elevation
Study
n = 35
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
10 microg single dose · subcutaneous · up to 8 h postprandiallyAs given in this study (human).
Source sentences
Summary
Exenatide markedly reduced postprandial elevation of TG, apolipoproteins B-48 and CIII, RLP-cholesterol and RLP-triglyceride (all p<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
A double-blinded, randomized, placebo-controlled, crossover study was conducted in 35 subjects (31 men and 4 women) with impaired glucose tolerance (n=20) or recent onset type 2 diabetes (n=15).
Summary · context
A single subcutaneous injection of exenatide (10 microg) or normal saline was administered just prior to a high-calorie, fat-enriched breakfast meal.
Summary · context
Concentrations of triglycerides (TG), apolipoproteins B-48 and CIII, non-esterified fatty acids (NEFA), and remnant lipoprotein (RLP) cholesterol and TG in serum or plasma were measured prior to the injection and for up to 8 h postprandially.
Report a problemFND-2055788701
02HumanRandomized controlled trialEfficacy outcome
In people with impaired glucose tolerance or recent type 2 diabetes, exenatide reduced postprandial apolipoprotein B-48 elevation versus placebo.
In plain wordsIn people with impaired glucose tolerance or recent diabetes, exenatide reduced apolipoprotein B-48 rises after meals versus placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePostprandial apolipoprotein B-48 elevation
Study
n = 35
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
10 microg single dose · subcutaneous · up to 8 h postprandiallyAs given in this study (human).
Source sentences
Summary
Exenatide markedly reduced postprandial elevation of TG, apolipoproteins B-48 and CIII, RLP-cholesterol and RLP-triglyceride (all p<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
A double-blinded, randomized, placebo-controlled, crossover study was conducted in 35 subjects (31 men and 4 women) with impaired glucose tolerance (n=20) or recent onset type 2 diabetes (n=15).
Summary · context
A single subcutaneous injection of exenatide (10 microg) or normal saline was administered just prior to a high-calorie, fat-enriched breakfast meal.
Summary · context
Concentrations of triglycerides (TG), apolipoproteins B-48 and CIII, non-esterified fatty acids (NEFA), and remnant lipoprotein (RLP) cholesterol and TG in serum or plasma were measured prior to the injection and for up to 8 h postprandially.
Report a problemFND-2055788702
03HumanRandomized controlled trialEfficacy outcome
In people with impaired glucose tolerance or recent type 2 diabetes, exenatide reduced postprandial apolipoprotein CIII elevation versus placebo.
In plain wordsIn people with impaired glucose tolerance or recent diabetes, exenatide reduced apolipoprotein CIII rises after meals versus placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePostprandial apolipoprotein CIII elevation
Study
n = 35
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
10 microg single dose · subcutaneous · up to 8 h postprandiallyAs given in this study (human).
Source sentences
Summary
Exenatide markedly reduced postprandial elevation of TG, apolipoproteins B-48 and CIII, RLP-cholesterol and RLP-triglyceride (all p<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
A double-blinded, randomized, placebo-controlled, crossover study was conducted in 35 subjects (31 men and 4 women) with impaired glucose tolerance (n=20) or recent onset type 2 diabetes (n=15).
Summary · context
A single subcutaneous injection of exenatide (10 microg) or normal saline was administered just prior to a high-calorie, fat-enriched breakfast meal.
Summary · context
Concentrations of triglycerides (TG), apolipoproteins B-48 and CIII, non-esterified fatty acids (NEFA), and remnant lipoprotein (RLP) cholesterol and TG in serum or plasma were measured prior to the injection and for up to 8 h postprandially.
Report a problemFND-2055788703
04HumanRandomized controlled trialEfficacy outcome
In people with impaired glucose tolerance or recent type 2 diabetes, exenatide reduced postprandial RLP-cholesterol elevation versus placebo.
In plain wordsIn people with impaired glucose tolerance or recent diabetes, exenatide reduced remnant lipoprotein cholesterol rises after meals versus placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePostprandial RLP-cholesterol elevation
Study
n = 35
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
10 microg single dose · subcutaneous · up to 8 h postprandiallyAs given in this study (human).
Source sentences
Summary
Exenatide markedly reduced postprandial elevation of TG, apolipoproteins B-48 and CIII, RLP-cholesterol and RLP-triglyceride (all p<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
A double-blinded, randomized, placebo-controlled, crossover study was conducted in 35 subjects (31 men and 4 women) with impaired glucose tolerance (n=20) or recent onset type 2 diabetes (n=15).
Summary · context
A single subcutaneous injection of exenatide (10 microg) or normal saline was administered just prior to a high-calorie, fat-enriched breakfast meal.
Summary · context
Concentrations of triglycerides (TG), apolipoproteins B-48 and CIII, non-esterified fatty acids (NEFA), and remnant lipoprotein (RLP) cholesterol and TG in serum or plasma were measured prior to the injection and for up to 8 h postprandially.
Report a problemFND-2055788704
05HumanRandomized controlled trialEfficacy outcome
In people with impaired glucose tolerance or recent type 2 diabetes, exenatide reduced postprandial RLP-triglyceride elevation versus placebo.
In plain wordsIn people with impaired glucose tolerance or recent diabetes, exenatide reduced remnant lipoprotein triglyceride rises after meals versus placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePostprandial RLP-triglyceride elevation
Study
n = 35
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
10 microg single dose · subcutaneous · up to 8 h postprandiallyAs given in this study (human).
Source sentences
Summary
Exenatide markedly reduced postprandial elevation of TG, apolipoproteins B-48 and CIII, RLP-cholesterol and RLP-triglyceride (all p<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
A double-blinded, randomized, placebo-controlled, crossover study was conducted in 35 subjects (31 men and 4 women) with impaired glucose tolerance (n=20) or recent onset type 2 diabetes (n=15).
Summary · context
A single subcutaneous injection of exenatide (10 microg) or normal saline was administered just prior to a high-calorie, fat-enriched breakfast meal.
Summary · context
Concentrations of triglycerides (TG), apolipoproteins B-48 and CIII, non-esterified fatty acids (NEFA), and remnant lipoprotein (RLP) cholesterol and TG in serum or plasma were measured prior to the injection and for up to 8 h postprandially.
Report a problemFND-2055788705
06HumanRandomized controlled trialEfficacy outcome
In people with impaired glucose tolerance or recent diabetes, postprandial NEFA declines were smaller but lasted longer with exenatide versus placebo.
In plain wordsIn people with impaired glucose tolerance or recent diabetes, fatty acid declines after meals were smaller but lasted longer with exenatide versus placebo.
Peptide
Exenatide (exendin-4)
Outcome
MixedPostprandial NEFA trajectory
Study
n = 35
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
10 microg single dose · subcutaneous · up to 8 h postprandiallyAs given in this study (human).
Source sentences
Summary
Postprandial declines in NEFA were less pronounced but persisted longer with exenatide compared to placebo (p<0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
A double-blinded, randomized, placebo-controlled, crossover study was conducted in 35 subjects (31 men and 4 women) with impaired glucose tolerance (n=20) or recent onset type 2 diabetes (n=15).
Summary · context
A single subcutaneous injection of exenatide (10 microg) or normal saline was administered just prior to a high-calorie, fat-enriched breakfast meal.
Summary · context
Concentrations of triglycerides (TG), apolipoproteins B-48 and CIII, non-esterified fatty acids (NEFA), and remnant lipoprotein (RLP) cholesterol and TG in serum or plasma were measured prior to the injection and for up to 8 h postprandially.
Report a problemFND-2055788706
07HumanRandomized controlled trialMechanism
In the crossover study, glucose tolerance status and statin treatment did not affect exenatide's postprandial lipid effects versus placebo.
In plain wordsIn people with impaired glucose tolerance or recent diabetes, glucose status and statins did not alter exenatide's lipid effects versus placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeModification by glucose tolerance status or statins
Study
n = 35
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
10 microg single dose · subcutaneous · up to 8 h postprandiallyAs given in this study (human).
Source sentences
Summary
These effects of exenatide were not affected either by glucose tolerance status or by treatment with statins.
5 context sentences(design, population, supporting numbers)
Summary · context
Exenatide markedly reduced postprandial elevation of TG, apolipoproteins B-48 and CIII, RLP-cholesterol and RLP-triglyceride (all p<0.001).
Summary · context
Postprandial declines in NEFA were less pronounced but persisted longer with exenatide compared to placebo (p<0.05).
Summary · context
A double-blinded, randomized, placebo-controlled, crossover study was conducted in 35 subjects (31 men and 4 women) with impaired glucose tolerance (n=20) or recent onset type 2 diabetes (n=15).
Summary · context
A single subcutaneous injection of exenatide (10 microg) or normal saline was administered just prior to a high-calorie, fat-enriched breakfast meal.
Summary · context
Concentrations of triglycerides (TG), apolipoproteins B-48 and CIII, non-esterified fatty acids (NEFA), and remnant lipoprotein (RLP) cholesterol and TG in serum or plasma were measured prior to the injection and for up to 8 h postprandially.
Report a problemFND-2055788707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT00974272

Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation

Carl T. Hayden VA Medical Centern = 39Aug 2006 to Nov 2008

Type 2 Diabetes Mellitus · Impaired Glucose Tolerance

Trial page ClinicalTrials.govUpdated 10 Sept 2009

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.